DEIRDRE C MCMULLEN, MD

Family Practitioner
dmcmullen@synergygroupus.com

AFFILIATED ADDRESSES

Synergy Groups Medical LLC
8121 Broadway Street, Suite 120/111 Houston, TX 77061
3281 Rocky Creek Dr. Ste. 500 Missouri City, TX 77459
10101 Bissonnet, #105 A-C, Houston, TX 77036

EDUCATION

Residency-Family Practice – 1999
Memorial Hermann Hospital, TX – USA

Doctor of Medicine – 1996
University of Texas (Med School @ Houston), TX – USA

Bachelor of Science – 1988
Trinity University, TX – USA

22 MAR 2024

LICENSE

1. Medical License, State of Texas- #K5622
2. Drug Enforcement Agency – Registration # BM6088101
3. NPI#1043206733

BOARD CERTIFICATION

- American Board of Medicine – Family Practice since 2006

TRAINING

- Collaborative Institutional Training Initiative (CITI) Good Clinical Practice: (Current)
- The National Institutes of Health (NIH): Completed 26Sep2018
- EDC(Current)
- Virtual Trial Capable Certified (Current)

LANGUAGE

1. Fluent in English

EXPERIENCE:

Principal/Sub-Investigator 2016-Present
Synergy Groups Medical LLC
(Previously Known as **Discovery MM Services, Inc.**)

Principal/Sub-Investigator 2011-2016
Gulf Coast Medical Research, TX

Private Practice 2003-Present
Deirdre McMullen, MD –P. A, TX

Staff Physician
Polly Ryun Medical Group, TX 2002-2003

Principal Investigator
Community Trial, TX 2000-2000

RESEARCH:

- Efficacy and long-term safety of oral XXXX versus XXXX in subjects with type 2 diabetes
- Dose-finding of XXXX administered subcutaneously once daily versus placebo and XXXX in subjects with type 2 diabetes
- An open Label, Randomized, Parallel- group, three treatment arm, multicenter study on Hypogonadal males to evaluate the effect on 24-hour ambulatory blood pressure after 16-week continuous treatment with marketed testosterone products
- Efficacy and safety of GMRx2 (a single pill combination containing telmisartan/amlodipine/ indapamide) compared to placebo for the treatment of hypertension: An international, multi center, randomized, double-blind, placebo controlled, parallel group trial
- A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy to usual care on LDL cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease and elevated LDL-C (>70 mg/dl) despite receiving maximally tolerated statin therapy (VICTORION- INITIATE)

- A randomized, double-blind, placebo-controlled, parallel- group, multicenter, event-driven Phase III study to investigate the efficacy and safety of XXXX in addition to standard of care, on the progression of kidney disease in subjects with T2DM and the clinical diagnosis of diabetic kidney disease

- A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic XXXX Ointment, 0.1% to the Marketed Product XXX: Xopic® ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis

- A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation of therapy in insulin naive patients with uncontrolled T2DM

- A randomized, double-blind, placebo-controlled, para1lel- group, multicenter, event-driven Phase III study to investigate the efficacy and safety of XXXX in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

- A 52 Week, Phase III Double-Blind, Randomized, Placebo- Controlled, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of XXXX in Subjects with Primary Hyperlipidemia at Risk of Cardiovascular

- A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of XXX XXXX in subjects with Acute Otitis Externa

- Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral XXXX in Subjects with Type 2 Diabetes

- A National, Randomized, 12-Week, Double-Blind, Placebo- Controlled Study to Assess the Safety and Efficacy of XXXX (Xmg and X mg) in Patients CIC

- The Efficacy of XXXX as Adjunct Therapy to Insulin in the Treatment of T1DM

- Efficacy and Safety of XXXX in Combination with Metformin versus Metformin Monotherapy on Glycemic Control in Children and Adolescents with T2DM

- Efficacy and Safety of XXXX Once-Weekly vs XXXX XX mg Once-Weekly Add-On to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects with Type 2 Diabetes

- A Trial Comparing Cardiovascular Safety of Insulin XXXX versus Insulin XXXX in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Event

- Principal Investigator-Study of XXXX to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS) Phase IV - Observational Study of the Use of XXXX in Adult Hyperuricemia Patients with Gout Refractory to Conventional Therapy

- Efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting

- *A* randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation

of therapy in insulin naive patients with uncontrolled type 2 diabetes mellitus

- A randomized 24-week, multi-center, randomized, open-label, parallel-group study comparing the efficacy and safety of Toujeo® and Tresiba® in insulin-naive patients with type 2 diabetes mellitus not adequately controlled with oral antidiabetic drug(s) ± GLP-1 agonist
- A 26-week randomized, open-label, active controlled, parallel-group, study assessing the efficacy and safety of the insulin XXX/XXX fixed ratio combination in adults with type 2 diabetes inadequately controlled on GLP-1 agonist and metformin ± pioglitazone, followed by a fixed ratio combination single-arm 26-week extension
- Second Phase III randomized, 12- week, double-blind, placebo-controlled study of the safety and efficacy of XXX in patients with irritable bowel syndrome with constipation (IBS-C)
- An open- label, long- term safety and tolerability study of XXXX in patients with irritable bowel syndrome with constipation (IBS-C)
- Getting to an improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia management (GOULD): a registry of High Cardiovascular Risk Subjects in the United States.
- A randomized, double-blind, placebo-controlled, parallel- group, multicenter, event-driven Phase III study to investigate the efficacy and safety of XXXX on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.
- Phase II, A Study on Efficacy and Safety of XXX in the treatment of patients with Obesity.
- An International Phase III, Randomized, Double-Blind, Placebo- and Active (XXX)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of XXX in Patients with Symptoms of Overactive Bladder
- An International Phase III, Randomized, Double-Blind, Active (XXX)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of XXX in Patients with Symptoms of Overactive Bladder
- A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combination of FF/VI, administered once-daily via a dry powder inhaler in subjects with inadequately controlled asthma
- Testosterone Replacement therapy for Assessment of long-Term Vascular Events and efficacy Response in hypogonadal Men (TRAVERSE) Study Phase: IV
- Evaluation of XXX ER XX and XX mg Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo Controlled, Pivotal Trial
- Evaluation of XXXX ER XX and XX mg Efficacy and Safety in Adolescents with ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
- Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of XXXX ER for the Treatment of Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD).

- Assessment of Efficacy and Safety of XXX-XXX for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment

- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended-Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis

- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of XXXXXX to XXXXXX in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

- A randomized, sham controlled, double-blind, multi-center study of Neuromuscular Electrical Stimulation (NMES) as an Adjunctive Therapy for Knee Pain Relief and Improving Functional Outcomes in Knee Osteoarthritis (OA) Patients

- A Randomized, Multicenter, Double-blind, Double-dummy, Parallel-group, Placebo and Active Comparator-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of XXXXXX in Gout Patients with Hyperuricemia

- A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral XXXX in Mild to Moderate Ulcerative Colitis

- A Double-Blind, Placebo-Controlled, Phase II, Responsive Adaptive Randomization Study of XXXX in Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)

- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of XXXX Administered Orally to Children, Ages 6 to 17 Years, With Functional Constipation (FC)

- Open-Label Extension Study to Evaluate the Long-Term Safety of XXXXX Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric and Adolescent Subjects with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment

- A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of XXXX for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND)

- A Phase II Randomized, Double Blind, Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Safety And Efficacy Of Repeated Oral Doses Of XXXX™ In Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C And IBS-D

- Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with

Standard ADHD Treatment

- A Phase III double-blind placebo-controlled efficacy trial of XXXXXX vaginal gel for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection
- An observational study to compare human saliva samples to nasopharyngeal swab specimens for COVID-19 detection
- A population based epidemiological XXXXX/XXXX registry and research project
- A randomized, controlled pragmatic Phase IIIB/IV study of XXXX in patients with rheumatoid arthritis
- A 52-week, Phase III double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of pf-xxxxxx in subjects with primary hyperlipidemia or mixed dyslipidemia at risk of cardiovascular events